Empiric Antibiotic Therapy for Adult Burn Patients with Suspected Infection
For adult burn patients with suspected infection, vancomycin plus an antipseudomonal beta-lactam (cefepime or piperacillin-tazobactam) is the recommended empiric regimen.
Rationale and Evidence Base
The most relevant guideline evidence comes from the IDSA MRSA guidelines 1, which specifically address complicated skin and soft tissue infections including infected burns. For hospitalized patients with complicated SSTI (which explicitly includes infected burns), empirical therapy for MRSA should be considered pending culture data, with options including IV vancomycin, linezolid, daptomycin, telavancin, or clindamycin, combined with broad-spectrum coverage 1.
Recent burn-specific research strongly supports this approach. A 2024 retrospective analysis of burn center pathogens demonstrated that vancomycin plus cefepime covered 98% of Gram-positive and 84% of all Gram-negative pathogens isolated within the first week of admission 2. In patients without healthcare-associated risk factors, coverage improved to 98% and 90% respectively 2.
Specific Regimen Recommendations
First-Line Empiric Therapy:
- Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 15-20 mcg/mL) 1
- PLUS one of the following antipseudomonal agents:
Alternative Regimens:
For beta-lactam allergies:
- Vancomycin PLUS ciprofloxacin 400mg IV every 12 hours 3
- Or vancomycin PLUS aztreonam 2g IV every 6-8 hours 5
For suspected multidrug-resistant Gram-negatives:
- Consider adding colistin if MDR Pseudomonas or Acinetobacter is suspected based on local epidemiology 4
- Carbapenems (meropenem 1g IV every 8 hours or imipenem 500mg IV every 6 hours) for ESBL-producing organisms 3
Critical Considerations
Pathogen Evolution Over Time:
Burn wound microbiology follows a predictable pattern: Gram-positive cocci (particularly Staphylococcus aureus) predominate initially, while Gram-negative organisms (Pseudomonas aeruginosa, Acinetobacter) emerge with prolonged hospitalization 4, 6. The most common pathogens isolated are Klebsiella pneumoniae (30.2%), Staphylococcus aureus (24.3%), and Pseudomonas aeruginosa (21.0%) 7.
When NOT to Use Antibiotics:
Routine antibiotic prophylaxis should NOT be administered to burn patients without evidence of infection 8. The 2020 European burn guidelines explicitly recommend against routine systemic antibiotic prophylaxis, citing low-quality evidence and risk of selecting multidrug-resistant bacteria 8. This aligns with Surviving Sepsis Campaign guidance against sustained antimicrobial prophylaxis in severe inflammatory states of noninfectious origin 9.
Duration and De-escalation:
- Initial empiric therapy should be narrowed within 3-5 days based on culture results 9
- Total duration typically 7-10 days, though longer courses may be needed for slow clinical response or persistent bacteremia 9
- Combination therapy should be discontinued once clinical improvement occurs 9
Common Pitfalls to Avoid
Using topical antibiotics as first-line treatment: Silver sulfadiazine and other topical antibiotics should be reserved for infected wounds only, not prophylaxis 8
Inadequate dosing in burn patients: Burn-induced hypermetabolism and altered pharmacokinetics may require higher doses, prolonged infusions, or therapeutic drug monitoring 10, 6
Failing to cover MRSA empirically: With MRSA prevalence high in burn units (particularly community-acquired strains), vancomycin should be included in initial regimens for suspected infection 1, 11
Overreliance on aminoglycosides: While gentamicin or amikacin show good sensitivity in some studies 12, 7, they should be reserved for combination therapy in severe septic shock rather than routine empiric use 9
Ignoring local resistance patterns: The specific regimen should be adjusted based on institutional antibiograms, particularly for MDR Gram-negative organisms 2, 10
Septic Shock Considerations
For burn patients presenting with septic shock, combination therapy is recommended 9. Add an aminoglycoside (gentamicin 7 mg/kg IV daily) or fluoroquinolone to the beta-lactam for enhanced Pseudomonas coverage, but discontinue within the first few days based on clinical response 9, 3.